Cyp2d6 Genotype - Pharma

Relevant Publications

Does cytochrome 2D6 genotype affect the analgesic efficacy of codeine after ambulatory surgery? Prospective trial in 987 adults.

Issue Release: 2025

The potential Role of CYP2D6*10(c.100 C>T) Gene Polymorphism in Kidney Injury of Patients with Hypertension Complicated with Non-Elevated Cystatin C.

Issue Release: 2024

Rationale and design for a pragmatic randomized trial to assess gene-based prescribing for SSRIs in the treatment of depression.

Issue Release: 2024

Effect of CYP2D6, 2C19, and 3A4 Phenoconversion in Drug-Related Deaths.

Issue Release: 2024

Exploring CYP2D6 polymorphisms and angiotensin receptor blocker response in the Bai hypertensive population.

Issue Release: 2024

Genetic susceptibility and clinical features of associated with systemic lupus erythematosus in a Chinese population.

Issue Release: 2024

Genetic analysis: Therapeutic drug monitoring of metformin and glimepiride on diabetic patients\' plasma including genetic polymorphism.

Issue Release: 2024

Evaluation of SLC6A2 and CYP2D6 polymorphisms\' effects on atomoxetine treatment in attention deficit and hyperactivity disorder.

Issue Release: 2024

Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together.

Issue Release: 2024

Effects of gene polymorphism on plasma concentration and therapeutic effect of olanzapine.

Issue Release: 2024

Comparative Analysis of Machine Learning Algorithms Evaluating the Single Nucleotide Polymorphisms of Metabolizing Enzymes with Clinical Outcomes Following Intravenous Paracetamol in Preterm Neonates with Patent Ductus Arteriosus.

Issue Release: 2024

Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data.

Issue Release: 2024

Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis.

Issue Release: 2024

CYP2B6 and ABCB1 genotypes predict methadone plasma exposure among patients on maintenance therapy against opioid addictions in Tanzania.

Issue Release: 2024

The impact of CYP2D6 on donepezil concentration and its lack of effect on the treatment response and adverse effect in Korean patients with Alzheimer\'s disease.

Issue Release: 2024

Effect of CYP2D6 genetic variation on patient-reported symptom improvement and side effects among children and adolescents treated with amphetamines.

Issue Release: 2024

The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.

Issue Release: 2024

Pharmacogenomic allele coverage of genome-wide genotyping arrays: a comparative analysis.

Issue Release: 2024

Prediction of combination effect of quinidine on the pharmacokinetics of tipepidine using a physiologically based pharmacokinetic model.

Issue Release: 2024

Frequencies of and gene variants in a German inpatient sample with mood and anxiety disorders.

Issue Release: 2024

What Should Be Included in Patient Education Materials?

Why is Medication Adherence Important?

Why is Regulatory Approval Important?

How Does the Patent System Affect Generic Competition?

Why is the Management of Chronic Conditions Important?

How Can Pharma Companies Improve Patient Education?

Who Can Participate in Clinical Trials?

What is Regulatory Approval?

What is a New Drug Application (NDA)?

Who are Pharmacists?

Cyp2d6 Genotype - Pharma

Relevant Publications

Partnered Content Networks

Relevant Topics